Therapeutics targeting the TLR/IFN pathway are in development for the treatment of SLE, with ongoing clinical trials investigating monoclonal antibodies against IFN-α and inhibitors for TLR7/TLR9 (reviewed in [2]). This evidence concerns the gene TLR7 and systemic lupus erythematosus.